Lataa...
Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups
Combined use of MammaPrint and a molecular subtyping profile (BluePrint) identifies disease subgroups with marked differences in long-term outcome and response to neo-adjuvant therapy. The aim of this study was to evaluate the prognostic value of molecular subtyping using MammaPrint and BluePrint in...
Tallennettuna:
| Julkaisussa: | Breast Cancer Res Treat |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer US
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4621695/ https://ncbi.nlm.nih.gov/pubmed/26424167 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3587-9 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|